CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 191 enrolled
Drug / intervention
propranolol LA +2 moredrug
Likely dose
propranolol LA 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00772031
NCT00772031Phase 3Completed
CompareCT.gov

NINDS Clinical Research Collaboration Chronic Migraine Treatment Trial

Anne Lindblad·interventional·Posted Oct 15, 2008·Updated Jan 24, 2012

In Brief

A Phase 3 clinical trial evaluating propranolol LA, topiramate, and 1 other intervention for Chronic Migraine. Completed, enrolled 191 participants across 39 sites.

Detailed Summary

The purpose of this study is to compare the reduction in the number of severe headache days at six months in people with chronic migraine treated with topiramate and propranolol versus those treated with topiramate and a placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Migraine
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS), Ortho-McNeil Janssen Scientific Affairs, LLC

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 15, 2008
Enrollment StartOct 1, 2008
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.7 years ago

Interventions

propranolol LAdrug

Propranolol LA up to 240 mg/day

topiramatedrug

Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.

placebodrug

an inactive substance